Research Paper Volume 13, Issue 1 pp 450—459

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis

Forest plots comparing acceptability of treatment discontinuation and QoL. (A) Treatment discontinuation; (B) QoL.

Figure 8. Forest plots comparing acceptability of treatment discontinuation and QoL. (A) Treatment discontinuation; (B) QoL.